Fibronectin in malignancy: Cancer-specific alterations, protumoral effects, and therapeutic implications

Semin Oncol. 2019 Jun;46(3):284-290. doi: 10.1053/j.seminoncol.2019.08.002. Epub 2019 Aug 27.

Abstract

Initial studies on cancer primarily focused on malignant cells themselves. The overarching narrative of cancer revolved around unchecked and rapidly proliferating cells. Special attention was given to the molecular, genetic, and metabolic profiles of isolated cancer cells in hopes of elucidating a critical factor in malignancy. However, the scope of cancer research has broadened over the past few decades to include the local environment around cancer. It has become increasingly apparent that the immune cells, vascular networks, and the extracellular matrix all have a part in cancer progression. The impact of the extracellular matrix is particularly fascinating and key stromal changes have been identified in various cancers. Pioneering work studying laminin and hyaluronate has shown that these molecules have vital roles in cancer progression. More recently, fibronectin has been included as an extracellular driver of malignancy. Fibronectin is thought to play a considerable, albeit poorly understood, role in cancer pathogenesis. In this review, we present fundamental studies that have investigated the impact of fibronectin in cancer. As an abundant component of the extracellular matrix, understanding the effect of this molecule has the potential to elucidate cancer biology.

Keywords: Cancer; Cancer signaling; ECM; Extra domain A; Extra domain B; Extracellular matrix; Fibronectin.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Disease Progression
  • Extracellular Matrix / genetics
  • Fibronectins / genetics*
  • Humans
  • Laminin / genetics
  • Medical Oncology / trends*
  • Neoplasms / genetics*
  • Neoplasms / metabolism
  • Neoplasms / pathology

Substances

  • Fibronectins
  • Laminin